In a study of Eli Lilly’s Zepbound, weight loss increased (PDF) from 20.9% after 36 weeks to 25.8% after 88 weeks. The top-line data shared by Novo Friday lack important details, including ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

and 3.9% among people taking placebo, Novo said Friday. Zepbound led to 20.9% weight loss over 72 weeks in its pivotal trial.

Weight loss was still increasing at Week 36, implying Kailera and Hengrui Pharma can go past 22.8%. The data suggest HRS9531 has similar efficacy to Eli Lilly’s Zepbound. Lilly won approval for ...

Those who received once-weekly semaglutide 7.2 mg lost 20.7% of their body weight on average after 72 weeks versus 17.5% weight loss with semaglutide ... Wegovy and Zepbound tipped to fuel $ ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Sales of blockbuster weight-loss drugs have surged in 2024 ... at a cheaper price. A four-week supply of the 2.5 mg Zepbound single-dose vials costs $399, while a four-week supply of the 5 mg ...

Jessica DeBenedetto has only been on compounded tirzepatide for a couple of weeks, but she already feels like it's a ...